REFERENCE
Hu M, Chen W.Cost effectiveness of telbivudine vs. entecavir and lamivudine among patients with HBeAg-positive chronic hepatitis B in china. 7th World Congress of the International Health Economics Association: abstr. 1103, 15 Jul 2009. Available from: URL: http://ihea2009.abstractbook.org
Rights and permissions
About this article
Cite this article
Compared with entecavir, telbivudine can improve health outcomes and is more cost effective. Pharmacoecon. Outcomes News 583, 8 (2009). https://doi.org/10.2165/00151234-200905830-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905830-00017